SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β<sub>1</sub>-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders. [PDF]
Turilli-Ghisolfi ES +6 more
europepmc +1 more source
Development of Novel Pegylated Imidazobenzodiazepines Targeting α5 GABAA Receptors for Anxiety: A Comparative Prodrug and Metabolite Study. [PDF]
Toriola MA +10 more
europepmc +1 more source
The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules. [PDF]
Hall BW +5 more
europepmc +1 more source
Thyroxin displacement from single and combined thyroid hormone binding proteins by various test substances. [PDF]
Brandt J +4 more
europepmc +1 more source
The Emergence of Isotryptamine Analogs as Novel Serotonergic Agents with Psychotherapeutic Potential. [PDF]
Glennon RA, Dukat M.
europepmc +1 more source
A new radioligand binding assay to measure the concentration of drugs in rodent brain ex vivo. [PDF]
Hussmann GP, Kellar KJ.
europepmc +1 more source
AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist. [PDF]
Patel M +4 more
europepmc +1 more source
A Structure-Activity Relationship Study of Alpha Synuclein PET Radiotracer M503-1619. [PDF]
Tian GL +11 more
europepmc +1 more source
Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery. [PDF]
McKenna SM +9 more
europepmc +1 more source
Development and Biological Characterization of Fluorescent Dynorphins for the Visualization of Kappa Opioid Receptors. [PDF]
Kalaba P +13 more
europepmc +1 more source

